| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Cy7-YNE does not bind to specific biological targets. Its reactive alkyne group serves as a chemical handle for click chemistry, specifically reacting with organic azides in the presence of a copper(I) catalyst. The reaction forms a stable 1,2,3-triazole linkage, covalently conjugating the Cy7 fluorophore to the azide-labeled biomolecule. After conjugation, the Cy7 fluorophore (a cyanine dye) can be excited by NIR light and emit NIR fluorescence for imaging applications. No biological target engagement beyond the chemical reaction occurs.
|
|---|---|
| ln Vitro |
Cy7-YNE has no intrinsic biological activity as a free dye. Its utility is purely chemical: to introduce a NIR-fluorescent tag onto biomolecules of interest (e.g., targeting ligands, antibodies). After conjugation, the labeled probe retains its target-binding ability (e.g., an antibody-Cy7 conjugate still binds to its antigen). The Cy7 dye is highly stable, exhibits excellent photostability, and has a high extinction coefficient (>200,000 M-¹cm-¹), providing bright fluorescence for sensitive detection. The alkyne click reaction is highly specific and does not cross-react with endogenous functional groups.
|
| ln Vivo |
The in vivo activity of Cy7-YNE is determined by the conjugated biomolecule to which it is attached (e.g., tumor-targeting antibody, RGD peptide). After conjugation and i.v. injection into tumor-bearing mice, Cy7-labeled targeting agents allow real-time, non-invasive fluorescence imaging of deep-seated tumors using near-infrared imaging systems. The Cy7 label provides deep tissue penetration (NIR window, 700-900 nm) because biological tissues (blood, skin, fat) exhibit minimal absorbance and autofluorescence at these wavelengths. This enables high-contrast visualization of tumor margins, lymph node metastases, and intraoperative fluorescence-guided surgery.
|
| Enzyme Assay |
The alkyne-azide cycloaddition is not a “receptor binding” assay. However, the reactivity of Cy7-YNE is confirmed by in vitro click chemistry. A model azide compound (e.g., 4-azidobenzoic acid, benzyl azide, or azide-PEG3-biotin) is dissolved in water/DMSO (1:1). In a reaction vial, Cy7-YNE (10 microM), the azide (10-100 microM), CuSO4 (100 microM), sodium ascorbate (500 microM), and a copper-stabilizing ligand (e.g., TBTA, 100 microM) are mixed in PBS (pH 7.4). The reaction proceeds at room temperature for 1-2 hours. Completion is monitored by LC-MS or by TLC (silica, chloroform:methanol 9:1, Rf values: Cy7-YNE ~0.4, product ~0.2). The reaction efficiency (>90% conversion) is confirmed by disappearance of the alkyne peak. For a negative control, omit the copper catalyst (no reaction).
|
| Cell Assay |
No cell-based assays for the free Cy7-YNE exist because it is a chemical linker. However, after conjugation, the labeled molecule can be tested in cellular binding or uptake experiments. For example, an EGFR-targeting antibody is labeled with Cy7 using Cy7-YNE (via a bioconjugation workflow: first azidylation of the antibody using NHS-PEG4-azide, then click reaction with Cy7-YNE). The Cy7-labeled antibody (10 microg/mL) is incubated with EGFR-positive A431 cells (cancer cell line) at 4degC (binding) or 37degC (internalization) for 1 hour. After washing away unbound antibody, cells are fixed with 4% paraformaldehyde and imaged by confocal microscopy with NIR excitation (Cy7 filter set). Specific cell surface staining is observed only in EGFR-positive cells but not in EGFR-negative cells, confirming that the conjugated antibody remains functional.
|
| Animal Protocol |
Cy7-YNE itself is not administered to animals. The Cy7-labeled targeting probe derived from it is used in imaging studies. A typical protocol: female athymic nude mice (6-8 weeks) bearing subcutaneous U87MG glioblastoma xenografts (tumor volume ~200-400 mm3) are injected intravenously (tail vein, 200 microL volume) with a Cy7-labeled tumor-targeting agent (e.g., anti-EGFR affibody-Cy7, 2-10 nmol dye equivalent per mouse). At predetermined time points (1, 4, 8, 12, 24, 48, 72 hours), mice are anesthetized with 2% isoflurane in oxygen. Whole-body fluorescence images are acquired using an IVIS Spectrum or Pearl Imager with NIR fluorescence settings (Ex: 710-760 nm, Em: 790-840 nm, binning: medium, exposure time: 0.5-2 seconds). At the final time point, mice are euthanized, and organs (tumor, liver, kidney, spleen, lung, heart, intestine, muscle, bone) are excised and imaged ex vivo to quantify probe accumulation. Tumor-to-muscle and tumor-to-liver ratios are calculated. The bright fluorescence of Cy7 allows deep-tissue imaging to detect small metastases (down to <1 mm).
|
| ADME/Pharmacokinetics |
Since Cy7-YNE is a reactive small molecule (MW ~700-1000), it is rapidly cleared from circulation if injected intravenously. The half-life would be minutes. However, it is never administered as the free alkyne; it is first conjugated to a carrier. The PK properties of the conjugate are determined by the biomolecule carrier (e.g., antibody: half-life days-weeks; peptide: half-life minutes-hours). The Cy7 dye itself is not metabolized by CYP enzymes; it is stable. Conjugates are cleared primarily by the liver (hepatobiliary) and renal pathways depending on size. The dye may accumulate in the liver and spleen due to reticuloendothelial system uptake, which is typical for nanoparticles and large conjugates. For antibody conjugates, terminal half-life in mice is 5-10 days.
|
| Toxicity/Toxicokinetics |
Cy7-YNE is a research chemical and should be handled with care. The acute oral toxicity is likely low, but no specific LD50 data are available. The compound can cause eye, skin, and respiratory tract irritation. Contact with skin should be avoided; in case of contact, wash with soap and water. The alkyne group is not considered highly toxic. The copper catalyst used in click chemistry (CuSO4/sodium ascorbate) is toxic to cells and animals at high concentrations but is not co-administered in vivo (excess catalyst is removed after conjugation). The final purified Cy7 conjugate contains negligible residual copper. No mutagenicity or carcinogenicity data are reported for Cy7-YNE. Standard laboratory precautions (gloves, lab coat, safety goggles) are required during handling. Cy7-YNE is for research use only, not for human diagnostic or therapeutic use.
|
| Additional Infomation |
Cy7-YNE is a near-infrared (NIR) fluorescent dye (Cy7, heptamethine cyanine) modified with a terminal alkyne (yne) group. The NIR region (700-1000 nm) is optimal for in vivo imaging due to minimal tissue absorption and autofluorescence, enabling deep tissue penetration (1-2 cm). The alkyne group is a handle for copper-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry, enabling covalent conjugation to azide-labeled molecules (e.g., azidated antibodies, azido-sugars, azido-nucleotides). This product is widely used for pre-targeted imaging strategies, cell tracking, and intraoperative fluorescence-guided surgery. Cy7-YNE is not approved for human use; it is strictly for research purposes. Store as a powder at -20degC, protected from light. Stock solutions (1-10 mM in anhydrous DMSO) are stable for several months at -20degC under inert atmosphere (Ar or N2) to prevent oxidation. The TFA salt form (if present) improves water solubility after neutralization.
|
| Molecular Formula |
C38H45N3O7S2
|
|---|---|
| Molecular Weight |
719.91
|
| Appearance |
Light yellow to green yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~50 mg/mL (~69.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.47 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3891 mL | 6.9453 mL | 13.8906 mL | |
| 5 mM | 0.2778 mL | 1.3891 mL | 2.7781 mL | |
| 10 mM | 0.1389 mL | 0.6945 mL | 1.3891 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
